COLD SPRING HARBOR, N.Y., Nov. 4, 2010 /PRNewswire/ -- AccuVein LLC, the developer of the first non-contact, handheld vein illumination system, announced today that it had been awarded the maximum grant amount from the Qualifying Therapeutic Discover Project (QTDP) program. This Federal grant program supports projects that show significant potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of health care costs.
AccuVein's AV300 helps health care professionals locate veins for blood draw, IV infusion and blood donation by projecting a pattern of light on patient's skin that reveals the position of underlying veins. This 10-ounce, hand-held device is available with a range of hands-free options so that it can quickly free the practitioner's hands to perform the venipuncture. It is the first and only system of its kind.
"Hospitals are adopting vein visualization as the standard-of-care for venipuncture as a tool to reduce error, reduce cost and increase patient satisfaction," said AccuVein engineering vice president Joe Zott. "Winning this grant will support our continued investment in delivering the best vein illumination system in the market."
AccuVein LLC is a supplier of innovative, cutting-edge medical devices. The award winning AV300 allows health care providers to see a map of the position of peripheral veins on the skin's surface with the goal of helping to improve venipuncture procedures. Built using AccuVein's expertise in medical device miniaturization and user-intuitive design, the AV300 is the world's first portable, non-contact vein illumination solution. The AccuVein AV300 was the recipient of the 2010 Medical Design Excellence Award and was cited as a 2009 best new product in Contemporary Pediatrics Magazine. AccuVein has filed applications for more than a dozen patents on the AV300's technology. It is in use at more than 400 U.S. hospitals and available for sale in over 50 countries. For more information on AccuVein's AV300, please visit www.accuvein.com.
Copyright©2010 PR Newswire.
All rights reserved